初创公司耐受性制药以1.3亿美元的交易获得了人类公司Btk项目的许可

Pharmadeals Review Pub Date : 2012-10-05 DOI:10.3833/PDR.V2012I5.1740

Heather Cartwright

{"title":"初创公司耐受性制药以1.3亿美元的交易获得了人类公司Btk项目的许可","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1740","DOIUrl":null,"url":null,"abstract":"In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I5.1740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I5.1740\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I5.1740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在一项价值约1.3亿美元的交易中，初创公司Tolero Pharmaceuticals获得了开发和商业化MannKind公司Btk (Bruton’s酪氨酸激酶)项目化合物的全球权利，该项目正在开发用于治疗血液恶性肿瘤和炎症性疾病。有趣的是，MannKind保留在第一阶段研究完成后60天内以预先规定的条款重新收购Btk资产的权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal

In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量